A phase-IV, Open-Label, interventional, prospective, single arm Trial of Soreze Advance Gel for treatment of Pressure Ulcer Healing and Wound Care in Adult Subjects

All patients meeting the inclusion criteria, with grade II and grade III ulcers, who sign the informed consent will be recruited for this single-arm, open-label study. Data on the primary endpoint, which is pressure ulcer size (stage, length, width, and depth), will be collected through clinician measurements and photographic documentation. Secondary endpoints will include infection status (including signs/symptoms of infection), amount and type of exudate, wound tissue color and type, and adverse events, all recorded at baseline. The wound surface area (length x width), exudate amount, and tissue type will be documented using the PUSH tool, and a baseline PUSH score will be calculated. Subjects will apply the investigational product twice daily, and information collected at each follow-up visit will include pressure ulcer size (length, width, depth via clinician measurement with photographic documentation), PUSH sub-scores and total score, time to complete wound closure, infection status, and adverse events.